Conference
A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial
Authors
Mackay H; Hirte HW; Covens A; MacAlpine K; Wang L; Tsao MS; Pan J; Zwiebel JA; Oza AM
Volume
26
Pagination
pp. 5518-5518
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2008
DOI
10.1200/jco.2008.26.15_suppl.5518
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X